Drugs to Target Cancer Tumor Genes

A new approach to fighting cancer will begin to accelerate this summer when the National Cancer Institute begins a clinical trial in which both approved and experimental drugs are used to target genetic mutations of a cancerous tumor instead of treating an entire organ where the tumor is located.

The trial, called NCI-MATCH, will involve DNA sequencing of 3,000 patients, with 1,000 of them moving on to the drug treatment phase. The DNA sequencing will be used to determine what molecular mutation is driving the tumor and then match that driver to the appropriate treatment option.

Drugs being used in the trial are both approved and experimental from various companies, such as Pfizer Inc.'s lung cancer drug crizotinib and Boehringer Ingelheim's afatinib.

People can enroll in the clinical trial through 2,400 sites participating in the National Clinical Trials Network.

NEXT: Obesity Raises AFib Risk

Sourced from: reuters.com, Large U.S. cancer trial to match genetic glitches to targeted drugs